secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspira Women's Health Inc. (AWHL)
CIK:        0000926617
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001493152-24-045354
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspira Women's Health Q3 rev $2.3M, cash burn $2.9M, reaffirms FY 2024 cash guidance
--------------------------------------------------------------------------------

- Q3 OvaSuite revenue $2.3M (+2% YoY); test volume 6,001 units (+4% YoY).
- OvaWatch volume grew 27% YoY, now 22% of total test volume.
- Cash used in ops $2.9M, down 12% from Q2; FY 2024 cash burn guidance reaffirmed $13.0-14.5M.
- Awarded $10M ARPA-H contract for ENDOinform; expects first $2M payment by year-end.
- Gross margin 60% (vs 59% YoY); sales & marketing up 26% but G&A down 25%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/926617/000149315224045354/0001493152-24-045354-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/926617/000149315224045354/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-045354

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer